bluebird bio, Inc. (BLUE), a biotechnology company, Carlyle (CG) and SK Capital Partners, LP Wednesday said they have amended their agreement pursuant to which Carlyle and SK Capital will purchase all outstanding shares of bluebird. bluebird bio shares were more than 50% up in pre-market.
As per the amended agreement, bluebird stockholders can elect to receive either the original offer of $3 per share in cash plus a contingent value right (CVR) of $6.84 per share in cash payable upon achieving a sales target, or $5 per share in cash.
The companies noted that stockholders who have previously tendered their shares and now choose to receive $5 per share must withdraw and re-tender their shares.
The amended tender offer expires on May 29.
As announced earlier, Carlyle and SK Capital have received all required regulatory approvals to complete the transaction.
bluebird bio stock had closed at $3.31, up 0.61% on Tuesday. It has traded in the range of $3.20 - 28.60 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.